Spiros Denaxas

This study identifies 80 genetic loci and 61 effector genes associated with dilated cardiomyopathy through GWAS and integrates transcriptomic data to uncover biological pathways and cellular states involved in the disease.

The paper identifies 679 diseases associated with increased risk for severe COVID-19 and Long COVID using UK Biobank health records, highlighting complex multimorbidity patterns and genetic risk loci.

The paper investigates sex differences in the genetic regulation of the plasma proteome and finds most genetic effects are similar between sexes, with few sex-differential effects that do not translate to disease risk.

This paper identifies genetic loci associated with short and long sleep duration through a cross-population meta-analysis and explores their genetic correlations and causal relationships with depression.

This paper uses Mendelian randomization to examine causal relationships between glycaemia, cognitive function, brain structure, and dementia in UK Biobank data, finding little evidence of causal associations.

This study evaluates how polygenic risk scores for coronary artery disease (CAD) relate to future events in individuals with and without CAD, finding attenuated or inverse associations in established cases.

The paper analyzes genetic variants at the PCSK9 locus to assess their phenotypic effects on lipid levels and disease outcomes, finding concordance with PCSK9 inhibitor trials for myocardial infarction but discordance for type 2 diabetes.

This study conducts a large GWAS on heart failure, identifying 12 genetic loci with associations to CAD, atrial fibrillation, and reduced left ventricular function, and provides causal evidence for several risk factors.

This study analyzes 70 EHR phenotyping algorithms from CALIBER and UK Biobank to understand their heterogeneity and identify common implementation patterns for developing a minimum information standard.

The paper discusses how integrating druggable target genes with disease susceptibility genes can improve drug development success rates by reducing target specification errors.